Special Issue "Immunometabolism in Mycobacterium tuberculosis (M.tb) Infection"

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Molecular Microbiology and Immunology".

Deadline for manuscript submissions: 15 January 2024 | Viewed by 1758

Special Issue Editors

Instructor in Medicine, Division of Infectious Diseases, Washington University School of Medicine, St louis, MO, USA
Interests: Mycobacterium tuberculosis pathogenesis; immunometabolism; autophagy
New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA
Interests: vaccines; innate immunity; macrophages; neutrophils; inflammation

Special Issue Information

Dear Colleagues,

Tuberculosis (TB) is a leading infectious disease killer worldwide and is only second to COVID-19. Mycobacterium tuberculosis, the pathogen that causes TB, has the ability to persist in its host and evade multiple antimicrobial mechanisms. M. tuberculosis infection can result in diverse clinical outcomes such as latent asymptomatic infection, active pulmonary disease, and extrapulmonary manifestations. Global efforts to eradicate TB are marred by an alarming increase in multi-drug resistant infections. Thus, there is a pressing need for an advanced understanding of this disease for the development of novel therapies. Recent years have seen substantial research investigating the impact of cellular metabolism on immunity with respect to M. tuberculosis. How host and pathogen influence cellular metabolism and how these interactions shape infection outcomes are poorly understood.

As the Guest Editor of this Special Issue, I invite you to submit original research articles, short communications, and review articles related to immunometabolism in M. tuberculosis pathogenesis. Research articles and short communications may describe metabolic dysfunction underlying inadequate immune responses to M. tuberculosis infection alone or during comorbidities, and metabolic perturbations and metabolites that enhance immunity against TB. Reviews should present the latest advancements in our understanding of immunometabolic crosstalk during M. tuberculosis infections and address gaps in current knowledge. Future investigations into this evolving discipline will contribute to an improved understanding of M. tuberculosis pathogenesis and aid in the development of TB therapies and biomarkers.

This Special Issue is jointly organized with the Special Issue “Mycobacterial Pathogenesis, Drug Resistance and Intervention Strategies“ in journal Medicina

Dr. Pallavi Chandra
Dr. Selvakumar Subbian
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolism
  • immunity
  • immunometabolism
  • tuberculosis, Mycobacterium tuberculosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Evaluation of the Toxic Activity of the Graphene Oxide in the Ex Vivo Model of Human PBMC Infection with Mycobacterium tuberculosis
Microorganisms 2023, 11(3), 554; https://doi.org/10.3390/microorganisms11030554 - 22 Feb 2023
Viewed by 940
Abstract
Graphene Oxide has been proposed as a potential adjuvant to develop improved anti-TB treatment, thanks to its activity in entrapping mycobacteria in the extracellular compartment limiting their entry in macrophages. Indeed, when administered together with linezolid, Graphene Oxide significantly enhanced bacterial killing due [...] Read more.
Graphene Oxide has been proposed as a potential adjuvant to develop improved anti-TB treatment, thanks to its activity in entrapping mycobacteria in the extracellular compartment limiting their entry in macrophages. Indeed, when administered together with linezolid, Graphene Oxide significantly enhanced bacterial killing due to the increased production of Reactive Oxygen Species. In this work, we evaluated Graphene Oxide toxicity and its anti-mycobacterial activity on human peripheral blood mononuclear cells. Our data show that Graphene Oxide, different to what is observed in macrophages, does not support the clearance of Mycobacterium tuberculosis in human immune primary cells, probably due to the toxic effects of the nano-material on monocytes and CD4+ lymphocytes, which we measured by cytometry. These findings highlight the need to test GO and other carbon-based nanomaterials in relevant in vitro models to assess the cytotoxic activity while measuring antimicrobial potential. Full article
(This article belongs to the Special Issue Immunometabolism in Mycobacterium tuberculosis (M.tb) Infection)
Show Figures

Figure 1

Back to TopTop